Stock LLM Wiki

報告_MS_工業自動化JMTBA_20260709

更新 2026-07-13

PDF 原檔:報告_MS_工業自動化JMTBA_20260709_original.pdf

圖片清單(已驗證 2026-07-13)

檔名 size 分類 親眼所見內容
報告_MS_工業自動化JMTBA_20260709_001.png 67KB 裝飾·logo·banner 藍色海面泳池橫幅,寫有「Asia Summer School 2026」,右側信封圖示。
報告_MS_工業自動化JMTBA_20260709_002.png 74KB 真資料圖 折線圖為 AirTAC 股價與紅色虛線目標價階梯走勢(2023/07–2026/07),最新目標價標示 2000(前一階為 1350)。
報告_MS_工業自動化JMTBA_20260709_003.png 74KB 真資料圖 折線圖為上銀股價與紅色虛線目標價階梯走勢(2023/07–2026/07),最新目標價標示 400(前一階為 380)。

兩張真資料圖之目標價數值與 2026-06-25 報告(報告_MS_工業自動化亞德客1590上銀2049_20260625)已嵌入公司頁的同類走勢圖一致(AirTAC TP 2000、上銀 TP 400),僅時間軸延伸,未嵌入 lib 頁避免重複圖表堆疊。

原始內容

M July 9, 2026 05:59 PM GMT

Greater China Technology Hardware | Asia Pacific

Automation - Read-across from Preliminary JMTBA June 2026 Orders

In this report, we focus on preliminary JMTBA orders, which we believe could be a catalyst for AirTAC's and Hiwin's share prices.

According to the Japan Machine Tool Builders' Association (JMTBA), headline orders grew 15% MoM and 53% YoY in June 2026 (vs. -6% MoM/+38% YoY in May 2026), to ¥204bn.

  • Domestic orders were +28% MoM/+46% YoY (vs. -8% MoM/+37% YoY in May), at ¥58bn.
  • Overseas orders were +10% MoM/+56% YoY (vs. -6% MoM/+38% YoY in May), at ¥145bn.

Our view:

  • Overseas orders saw some seasonal rebound on a sequential basis and stay strong on a YoY basis, consistent with the solid manufacturing PMIs from three major regions - China, Europe and North America at 50.3, 51.4 and 53.3 in May vs. 50.0, 51.6 and 54.0 in May.
  • We remain OW on both AirTAC (1590.TW) and Hiwin (2049.TW), as we see company-specific drivers on top of the industry recovery trend:
  • ° AirTAC should continue to benefit from its own market share gain, and valuation appears undemanding at 20x 2027e P/E (vs. 25x average since 2020).
  • ° Hiwin should see margin expansions in the coming quarters, driven by higher utilization and price hikes, which we believe could be share price catalysts. Though the current valuation of 31x 2027 P/E does not look cheap, we note that its peak cycle valuation could be up to 35-40x P/E.

Idea

Morgan Stanley Taiwan Limited+

Derrick Yang

Equity Analyst

Derrick.Yang@morganstanley.com

+886 2 2730-2862

Vivi Huang

Research Associate

Vivi.Huang@morganstanley.com

+886 2 2730-2860

Morgan Stanley Asia Limited+

Andy Meng, CFA

Equity Analyst

Andy.Meng@morganstanley.com

+852 2239-7689

報告_MS_工業自動化JMTBA_20260709_001

Greater China Technology Hardware

Asia Pacific

Industry View

In-Line

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

M

Catalyst Event Reaction

Company / Catalyst Date Impact to thesis Catalyst versus expectation
AirTAC International 1590.TW
Preliminary June 2026 JMTBA orders 09 Jul 2026 Unchanged In-line
Hiwin Technologies Corp. 2049.TW
Preliminary June 2026 JMTBA orders 09 Jul 2026 Unchanged In-line

M

Valuation Methodology and Risks

AirTAC International (1590.TW)

Base case, 30x 2027e P/E. We believe this methodology better captures earnings growth momentum for industrial automation component plays (market sentiment moves along with business cycles). As the industry enters an upcycle, we think applying a peak cycle valuation of 30x P/E is reasonable given the stronger business outlook.

Risks to Upside

  • n Stronger macroeconomic climate in China
  • n Stronger-than-expected demand from industrial automation

Risks to Downside

  • n Sharper economic downturn in China
  • n Miniature linear guideway business development taking more time
  • n Larger-than-expected investment in new products but weaker-than-expected demand

Hiwin Technologies Corp. (2049.TW)

Base case, P/E. We think this valuation methodology better captures Hiwin's earnings growth momentum, as its valuation tends to move with the business cycle. We apply a target multiple of 37x to our 2027 EPS estimate. We view this multiple as justified by the 44% operating profit CAGR we project for 2025-28.

Risks to Upside

  • n Stronger industrial automation demand pickup.
  • n Market share gains.
  • n Earlier-than-expected revenue contribution from humanoids.

Risks to Downside

  • n Weaker industrial automation demand.
  • n More pricing pressure.
  • n Market share loss.
  • n More broad-based impact on the global economy from geopolitical risks.

M

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ('SEBI') and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and their affiliates (collectively, "Morgan Stanley"). Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.